Parastomal Hernia — Role of Prosthetic Mesh in Preventing Parastomal Hernias
Citation(s)
Berger D Prevention of parastomal hernias by prophylactic use of a specially designed intraperitoneal onlay mesh (Dynamesh IPST). Hernia. 2008 Jun;12(3):243-6. Epub 2007 Dec 11.
Goligher JC Surgery of the anus, rectum and colon. 5th ed. London: Bailliere-Tindall; 1985.
Helgstrand F, Gögenur I, Rosenberg J Prevention of parastomal hernia by the placement of a mesh at the primary operation. Hernia. 2008 Dec;12(6):577-82. doi: 10.1007/s10029-008-0387-8. Epub 2008 Jun 4. Review.
Israelsson LA Preventing and treating parastomal hernia. World J Surg. 2005 Aug;29(8):1086-9. Review.
Jänes A, Cengiz Y, Israelsson LA Preventing parastomal hernia with a prosthetic mesh: a 5-year follow-up of a randomized study. World J Surg. 2009 Jan;33(1):118-21; discussion 122-3. doi: 10.1007/s00268-008-9785-4.
Janson AR, Jänes A, Israelsson LA Laparoscopic stoma formation with a prophylactic prosthetic mesh. Hernia. 2010 Oct;14(5):495-8. doi: 10.1007/s10029-010-0673-0. Epub 2010 May 23.
López-Cano M, Lozoya-Trujillo R, Espin-Basany E Prosthetic mesh in parastomal hernia prevention. Laparoscopic approach. Dis Colon Rectum. 2009 May;52(5):1006-7. doi: 10.1007/DCR.0b013e31819a6a58.
Rubin MS, Schoetz DJ Jr, Matthews JB Parastomal hernia. Is stoma relocation superior to fascial repair? Arch Surg. 1994 Apr;129(4):413-8; discussion 418-9.
Vijayasekar C, Marimuthu K, Jadhav V, Mathew G Parastomal hernia: Is prevention better than cure? Use of preperitoneal polypropylene mesh at the time of stoma formation. Tech Coloproctol. 2008 Dec;12(4):309-13. doi: 10.1007/s10151-008-0441-7. Epub 2008 Nov 18.
Prospective Randomized Study of the Role of Prosthetic Mesh in Preventing Parastomal Hernias in Patients With Definitive End Colostomy
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
